- Mechanism
- Stimulates GH release via GHS-R1a activation
- Typical research dose
- 200-300 mcg subcutaneous (research)
- Route
- Subcutaneous
- Half-life
- ~2 hours
- Legal status
- Research Only
Overview
Ipamorelin is a highly selective pentapeptide and ghrelin receptor agonist that stimulates the pituitary gland to release endogenous growth hormone. Unlike older growth hormone-releasing peptides (GHRPs), the Ipamorelin peptide does not significantly elevate cortisol or prolactin levels, making it a unique subject of clinical interest. Researchers are actively investigating Ipamorelin benefits for improving bone density, enhancing body composition, and accelerating gastrointestinal recovery following surgery.
Potential Benefits
- Enhanced Bone Density: Studies demonstrate that Ipamorelin induces longitudinal bone growth and counteracts glucocorticoid-induced decreases in bone formation in animal models (Johansen et al., 1999).
- Improved Body Composition: Research indicates that growth hormone secretagogues can help manage body composition by promoting lean muscle mass and reducing fat accumulation (Sinha et al., 2020).
- Gastrointestinal Recovery: Clinical trials have investigated Ipamorelin for the management of post-operative ileus, showing potential to accelerate the recovery of gastrointestinal function (NCT00672074).
- Prevention of Cachexia: Animal studies reveal that ghrelin agonists can inhibit chemotherapy-induced weight loss and exhibit anti-emetic effects (Lu et al., 2024).
- Orthopedic Tissue Repair: Emerging research in sports medicine highlights the potential of injectable peptide therapy to support tissue healing and joint recovery (Mayfield et al., 2026).
Where to Buy Ipamorelin
Research compound. Ipamorelin is a research chemical, typically not FDA-approved for human consumption. Sale or use for human consumption may be illegal in your jurisdiction.
No compensation. PeptideStack does not endorse, verify, or receive compensation from any vendor. No affiliate or referral relationships.
Verify third-party COAs and consult a qualified healthcare provider before using any compound.
Side Effects
Common side effects:
- Injection site reactions such as redness, swelling, or pain
- Mild headaches shortly after administration
- Temporary flushing or feeling of warmth
- Slight dizziness or lightheadedness
- Mildly increased appetite or hunger
Rare or serious side effects:
- Water retention or peripheral edema
- Changes in insulin sensitivity or blood glucose levels
- Numbness or tingling in extremities
- Joint pain associated with rapid fluid shifts
Ipamorelin is not FDA-approved and is intended for research purposes only. Consult a qualified healthcare provider before use.
Mechanism of Action
Selective receptor activation drives the primary mechanism of the Ipamorelin peptide, which binds specifically to the ghrelin/growth hormone secretagogue receptor (GHS-R1a) in the pituitary gland. This targeted binding stimulates a pulsatile release of growth hormone (GH) without significantly triggering the release of adrenocorticotropic hormone (ACTH), cortisol, or prolactin (Raun et al., 1998). The absence of these secondary hormonal spikes distinguishes it from earlier generation GHRPs, offering a more refined pharmacokinetic profile for researchers (Gobburu et al., 1999). Downstream signaling pathways activated by this GH surge subsequently stimulate the liver to produce Insulin-like Growth Factor 1 (IGF-1). Elevated IGF-1 levels mediate most of the systemic Ipamorelin benefits, including enhanced osteoblast activity for bone formation and increased protein synthesis in muscle tissues (Andersen et al., 2001). Furthermore, its action on GHS-R1a receptors in the gastrointestinal tract promotes gastric motility, explaining its utility in treating post-operative bowel dysfunction (NCT01280344).
Origin & History
Synthetic development of Ipamorelin began in the late 1990s as scientists sought to create a growth hormone secretagogue with higher specificity and fewer off-target effects. Developed jointly by Novo Nordisk and Helsinn Therapeutics, it was identified as the first selective growth hormone secretagogue that effectively bypassed the cortisol and prolactin elevations seen with GHRP-2 and GHRP-6 (Raun et al., 1998). Early pharmacokinetic modeling in human volunteers confirmed its predictable half-life and dose-dependent GH release, paving the way for targeted clinical applications. Clinical and regulatory milestones for Ipamorelin have primarily centered around its gastrointestinal applications rather than its systemic growth effects. It advanced through Phase 2 clinical trials to evaluate its safety and efficacy for managing post-operative ileus and recovering bowel function after surgery (NCT00672074). Despite promising early data, it remains an investigational compound with a research-only approval status, and is not currently approved by the FDA for human therapeutic use outside of clinical trials.